Epoxyeicosanoids in hypertension.

doi:10.33549/physiolres.934291

Paper

Epoxyeicosanoids in hypertension.

Published Oct 21, 2019 · J. Imig

Physiological research

Q2 SJR score

37

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Epoxyeicosatrienoic acid (EETs) are also known as epoxyeicosanoids that have renal and cardiovascular actions. These renal and cardiovascular actions can be regulated by soluble epoxide hydrolase (sEH) that degrades and inactivates EETs. Extensive animal hypertension studies have determined that EET vascular, epithelial transport, and anti-inflammatory actions lower blood pressure and decrease renal and cardiovascular disease progression. Human studies have also supported the notion that increasing EET levels in hypertension could be beneficial. Pharmacological and genetic approaches to increase epoxyeicosanoids in several animal models and humans have found improved endothelial vascular function, increased sodium excretion, and decreased inflammation to oppose hypertension and associated renal and cardiovascular complications. These compelling outcomes support the concept that increasing epoxyeicosanoids via sEH inhibitors or EET analogs could be a valuable hypertension treatment.

Study Snapshot

Increasing epoxyeicosanoids through sEH inhibitors or EET analogs may be a valuable hypertension treatment, improving endothelial vascular function, increasing sodium excretion, and decreasing inflammation.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Epoxyeicosanoids in hypertension.

References

Citations